对敏感性复发性卵巢癌的二次细胞还原手术:随机对照试验的元分析
Qingqing Lin1,2, Wenchao Liu3, Yanglong Guo4
1Department of Gynecology, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.
Archives of gynecology and obstetrics
|December 16, 2024
概括
对于敏感性复发性卵巢癌的二次细胞减少可以改善无进展生存率,但不能改善整体生存率. 在二次细胞减少过程中进行完全粗切除可以显著改善整体存活率和无进展存活率.
科学领域:
- 妇科瘤学 妇科瘤学
- 手术瘤学手术瘤学
- 临床研究 临床研究
背景情况:
- 对敏感的复发性卵巢癌在治疗选择中提出了挑战.
- 二次细胞减少是复发性疾病患者的潜在治疗策略.
研究的目的:
- 为了评估二次细胞减少的有效性,在白金敏感的复发性卵巢癌患者.
- 确定二次细胞减少对整体存活 (OS) 和无进展存活 (PFS) 的影响.
主要方法:
- 进行了随机对照试验 (RCT) 的系统审查和元分析.
- 搜索的数据库包括PubMed,Medline,Embase,Cochrane图书馆和科学网络.
- 对OS和PFS计算了聚合危险比率 (HR) 和95%置信区间 (CI).
主要成果:
- 二次细胞减少并没有显著改善OS (HR=0.89;95%CI 0.77,1.04;p=0.14).
- 二次细胞减少显著改善了PFS (HR=0.67;95% CI 0.54,0.76;p<0.00001).
- 完整的粗切除子组分析显示,OS (HR=0.70;95% CI 0.58-0.85;p=0.0003) 和PFS (HR=0.56;95% CI 0.48-0.66;p<0.00001) 均有显著的改善.
结论:
- 与单独的化疗相比,二次细胞减少改善了白金敏感性复发性卵巢癌的PFS,但并没有改善OS.
- 在二次细胞减少过程中实现完全粗切除可以显著延长OS,并增强PFS的益处.
- 完全粗切除是改善这一患者群体生存结果的关键因素.
更多相关视频
相关概念视频
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K


